In studying two subclones of the same human lung cancer cell line, one highly metastatic and the other poorly so, the authors concluded that robust IL-18 synthesis by the metastatic subclone was the determining factor in the different subclones’ behaviors, namely higher motility and metastatic competence in the higher IL-18–producing subclone. This evidence concerns the gene IL18 and lung cancer.